Progranulin and neuropathological features of Alzheimer’s disease: longitudinal study
Authors:
- Fardin NabizadehFNFardin Nabizadeh
- Alzheimer’s Disease Neuroimaging Initiative (Adni)A(Alzheimer’s Disease Neuroimaging Initiative (Adni)
Open Access
- 5 March 2024
- journal article
- research article
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 36 (1) , 1-10
Abstract
Background Progranulin is an anti-inflammatory protein that plays an essential role in the synapse function and the maintenance of neurons in the central nervous system (CNS). It has been shown that the CSF level of progranulin increases in Alzheimer’s disease (AD) patients and is associated with the deposition of amyloid-beta (Aβ) and tau in the brain tissue. In this study, we aimed to assess the longitudinal changes in cerebrospinal fluid (CSF) progranulin levels during different pathophysiological stages of AD and investigate associated AD pathologic features. Methods We obtained the CSF and neuroimaging data of 1001 subjects from the ADNI database. The participants were classified into four groups based on the A/T/N framework: A + /TN + , A + /TN−, A−/TN + , and A−/TN−. Results Based on our analysis there was a significant difference in CSF progranulin (P = 0.001) between ATN groups. Further ANOVA analysis revealed that there was no significant difference in the rate of change of CSF-progranulin ATN groups. We found that the rate of change of CSF progranulin was associated with baseline Aβ-PET only in the A−/TN + group. A significant association was found between the rate of change of CSF progranulin and the Aβ-PET rate of change only in A−/TN + Conclusion Our findings revealed that an increase in CSF progranulin over time is associated with faster formation of Aβ plaques in patients with only tau pathology based on the A/T/N classification (suspected non-Alzheimer’s pathology). Together, our findings showed that the role of progranulin-related microglial activity on AD pathology can be stage-dependent, complicated, and more prominent in non-AD pathologic changes. Thus, there is a need for further studies to consider progranulin-based therapies for AD treatment.Keywords
This publication has 55 references indexed in Scilit:
- Progranulin levels in blood in Alzheimer's disease and mild cognitive impairmentAnnals of Clinical and Translational Neurology, 2018
- Tau positron emission tomography imaging in tauopathies: The added hurdle of off‐target bindingAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2018
- Suspected non-Alzheimer's pathology – Is it non-Alzheimer's or non-amyloid?Ageing Research Reviews, 2017
- CSF Aβ1–42 – an excellent but complicated Alzheimer's biomarker – a route to standardisationClinica Chimica Acta, 2017
- Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP networkActa Neuropathologica, 2017
- Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement ActivationCell, 2016
- Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI)Brain Imaging and Behavior, 2012
- Progranulin promotes neurite outgrowth and neuronal differentiation by regulating GSK-3βProtein & Cell, 2010
- Total and phosphorylated tau protein as biological markers of Alzheimer’s diseaseExperimental Gerontology, 2010
- Progranulin expression correlates with dense‐core amyloid plaque burden in Alzheimer disease mouse modelsThe Journal of Pathology, 2009